



## Conference on ‘Carbohydrates in health: friends or foes’ Symposium 4: Whole grains, dietary fibre and grain-derived phytochemicals

### Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms?

Edward S. Chambers<sup>1\*</sup>, Douglas J. Morrison<sup>2</sup> and Gary Frost<sup>1</sup>

<sup>1</sup>*Faculty of Medicine, Nutrition and Dietetic Research Group, Section of Investigative Medicine, Hammersmith Campus, Imperial College London, UK*

<sup>2</sup>*Stable Isotope Biochemistry Laboratory, Scottish Universities Environmental Research Centre, University of Glasgow, East Kilbride, Glasgow, UK*

In recent years, there has been a renewed interest in the role of dietary fibre in obesity management. Much of this interest stems from animal and human studies which suggest that an increased intake of fermentable fibre can suppress appetite and improve weight management. A growing number of reports have demonstrated that the principal products of colonic fermentation of dietary fibre, SCFA, contribute to energy homeostasis via effects on multiple cellular metabolic pathways and receptor-mediated mechanisms. In particular, over the past decade it has been identified that a widespread receptor system exists for SCFA. These G-protein-coupled receptors, free fatty acid receptor (FFAR) 2 and FFAR3 are expressed in numerous tissue sites, including the gut epithelium and adipose tissue. Investigations using FFAR2- or FFAR3-deficient animal models suggest that SCFA-mediated stimulation of these receptors enhances the release of the anorectic hormones peptide tyrosine tyrosine and glucagon-like peptide-1 from colonic L cells and leptin from adipocytes. In addition, the SCFA acetate has recently been shown to have a direct role in central appetite regulation. Furthermore, the SCFA propionate is a known precursor for hepatic glucose production, which has been reported to suppress feeding behaviour in ruminant studies through the stimulation of hepatic vagal afferents. The present review therefore proposes that an elevated colonic production of SCFA could stimulate numerous hormonal and neural signals at different organ and tissue sites that would cumulatively suppress short-term appetite and energy intake.

#### Colonic fermentation: SCFA: Appetite: Gut hormone: Obesity

Recent longitudinal studies highlight that adults increase body weight gradually through middle age, with an average annual weight gain of approximately 0.5 kg<sup>(1,2)</sup>. This accumulation of body weight has resulted in an increased prevalence of obesity and its associated co-morbidities, as obesity incidence rates are now above 20 % in most Western countries and represent a major public health burden<sup>(3)</sup>. As a result, interventions that can be safely applied at the population level to prevent long-term weight gain would have major benefits to public health. It has been suggested that gradual adult weight gain can be the result of only a small habitual positive energy balance of 209.2–418.4 kJ/d

(50–100 kcal/d)<sup>(4)</sup>. Consequently, an improved understanding of the hormonal and neuronal signals that control appetite regulation may facilitate the development of novel dietary strategies that suppress energy intake and oppose a positive energy balance and long-term weight gain.

Epidemiological and experimental studies have consistently highlighted an inverse association between dietary fibre intake and body weight gain<sup>(5–7)</sup>. Furthermore, an increased intake of dietary fibre has been associated with improved appetite regulation<sup>(8)</sup>, thus making high-fibre diets an attractive strategy to reduce obesity levels. The current definition of dietary fibre<sup>(9)</sup> encompasses a diverse range

**Abbreviations:** ARC, arcuate nucleus; FFAR, free fatty acid receptor; GI, gastrointestinal; GLP, glucagon-like peptide; POMC, pro-opiomelanocortin; PYY, peptide tyrosine tyrosine.

\*Corresponding author: Edward S. Chambers, email e.chambers@imperial.ac.uk



of compounds with different chemical structures that influence their physiological effects. As a result, it has been proposed that dietary fibre can increase levels of satiation (the process that leads to the termination of eating) and satiety (the process that leads to inhibition of further eating after a meal has finished) by numerous mechanisms, depending on the natural properties of the ingested fibre<sup>(10)</sup>. Evidence suggests that the fermentable component of some dietary fibres may be important in promoting appetite regulatory effects and improvements in weight management<sup>(11)</sup>. Current Western diets contain energy-dense foods that are generally low in fibre (10–20 g/d) and high in sugars and fats<sup>(12)</sup>. This is in marked contrast to the Palaeolithic diet, which contained >100 g/d dietary fibre, to which the human gastrointestinal (GI) system has evolved over several millennia<sup>(13)</sup>. This ancestral diet was rich in indigestible plant material, which would have contained a large fermentable fibre component, and it has been suggested that the modern low-fibre diet fails to stimulate many satiation and satiety signals originating from the GI tract<sup>(14)</sup>. Dietary fibre passes through the small intestine unaffected by digestive enzymes, and upon reaching the colon, anaerobic bacteria are able to degrade some of these dietary fibres via a fermentation process that yields energy for the resident micro-organisms. The fermentability of dietary fibre varies, with resistant starches, NSP and non-digestible oligosaccharides being principal fermented substrates<sup>(15)</sup>. It has been estimated that the human gut microbiota consists of  $10^{13}$ – $10^{14}$  micro-organisms and is composed of approximately 1000 different species of bacteria, which belong to three principal phyla: *Bacteroidetes*, *Firmicutes* and *Actinobacteria*<sup>(16,17)</sup>. The main end-products of microbial fermentation are SCFA, heat and gases ( $\text{CO}_2$ ,  $\text{H}_2$  and  $\text{CH}_4$ )<sup>(18)</sup>. SCFA are classified as carboxylic acids that contain less than six carbon atoms. The most abundant (about 95 %) SCFA present in the human colon lumen are acetate ( $\text{C}_2$ ), propionate ( $\text{C}_3$ ) and butyrate ( $\text{C}_4$ ), in the approximate molar ratio 60 : 20 : 20<sup>(19)</sup>. The precise production of SCFA is difficult to measure in human subjects due to the inaccessibility of the colonic lumen. Furthermore, the formation of different SCFA can vary considerably between individuals due to large differences in gut microbial composition and activity<sup>(19)</sup>. Bacterial species that belong to the *Bacteroidetes* phylum mainly produce acetate and propionate, whereas the *Firmicutes* phylum primarily produces butyrate<sup>(18)</sup>. An investigation that measured SCFA directly from the human gut lumen reports that the highest concentrations are present in the proximal colon (about 120 mm/kg luminal contents) and these levels decrease distally through the colon<sup>(19)</sup>, revealing that SCFA are rapidly absorbed across the apical and basolateral membranes of colonocytes. It is estimated that fermentation of dietary fibre can yield 400–600 mm SCFA/d, which is equivalent to about 5–10 % of human energy requirements<sup>(20)</sup> and, furthermore, it has been consistently demonstrated in animals<sup>(21–24)</sup> and human subjects<sup>(25,26)</sup> that the amount of dietary fibre consumed has a considerable effect on the concentration of SCFA produced in the large bowel. The aim of the present review is to evaluate the possible mechanisms that may explain how an elevated colonic production

of SCFA could suppress short-term appetite responses and energy intake.

### Central nervous system control of appetite and energy intake

The hypothalamus and the brainstem are the main central nervous system regions responsible for the regulation of appetite and energy intake. These brain areas integrate the complex peripheral hormonal and neuronal signals that represent the current physiological state of the body<sup>(27,28)</sup>. The arcuate nucleus (ARC) within the hypothalamus senses hormones secreted into the peripheral circulation through a semipermeable blood–brain barrier. This nucleus contains two populations of neurons: (1) the orexigenic (appetite-stimulating) neuropeptide Y and agouti-related peptide and (2) the anorexigenic (appetite-suppressing) pro-opiomelanocortin (POMC) and cocaine and amphetamine-regulated transcript. Within the brainstem, the nucleus of the solitary tract integrates neural signals derived from stimulation of vagal afferents in the gut and other visceral tissues in response to chemical, mechanical and hormonal stimuli. There are extensive reciprocal connections between the hypothalamus and the brainstem and appetite responses and energy intake are coordinated on the basis of the hormonal and neural signals received by both brain regions<sup>(27,28)</sup>.

### SCFA receptors and anorectic gut hormone release

In 2003, it was demonstrated that SCFA act as ligands for the previously orphaned G-protein-coupled receptors GPR41 and GPR43<sup>(29–31)</sup>. These receptors have since been renamed free fatty acid receptor (FFAR) 3 and FFAR2, respectively. As G-protein coupled receptors, FFAR2 and FFAR3 are linked to heterotrimeric G-proteins attached to the cytoplasmic side of the receptor and stimulation of individual G-proteins trigger different cellular responses through the activation of specific secondary messenger cascades. FFAR2 couples to both  $\text{G}_{i/o}$ - (pertussis toxin-sensitive) and  $\text{G}_q$ -proteins (pertussis toxin-insensitive), whereas FFAR3 couples only to  $\text{G}_{i/o}$ -proteins<sup>(29,30)</sup>. Both FFAR2 and FFAR3 are activated by physiological concentrations of SCFA, although a preference of FFAR2 for acetate and propionate and of FFAR3 for propionate and butyrate has been reported<sup>(29–31)</sup>. These receptors have been shown to be expressed not only in the gut epithelium<sup>(32,33)</sup> where SCFA are produced and are at their highest concentrations, but also at multiple tissue sites, including adipose tissue<sup>(34–36)</sup>, immune cells<sup>(29)</sup>, skeletal muscle<sup>(31)</sup> and within the peripheral nervous system<sup>(37,38)</sup>. A possible role for these receptors in energy intake regulation emerged with the identification that FFAR2 and FFAR3 are present on colonic endocrine L-cells<sup>(32,33)</sup>. The L-cell is found at its highest density in the colonic epithelium<sup>(39)</sup> and secretes the anorexigenic hormones peptide tyrosine tyrosine (PYY) and glucagon-like peptide (GLP)-1<sup>(27)</sup>.

PYY is released into the circulation after food intake, with levels rising to a plateau after 1–2 h and remaining

elevated for up to 6 h<sup>(40)</sup>. Intravenous infusion of PYY to both lean and obese human subjects has been demonstrated to reduce energy intake<sup>(41,42)</sup>, and this anorexiogenic effect is thought to be exerted via neuropeptide Y inhibition and POMC activation in the hypothalamic ARC<sup>(41,43)</sup>. Peripheral vagal afferents are also involved in the appetite-suppressive action of PYY, as the hormone has been shown to stimulate the activity of gastric vagal nerves and vagotomy was reported to abolish the effect of PYY on feeding responses<sup>(44,45)</sup>.

GLP-1 is primarily recognised as an incretin, but it also fulfils several criteria in order to be considered a satiety signal. Circulating levels of GLP-1 rise following a meal in proportion to energy intake and are low in the fasted state<sup>(46)</sup>. Furthermore, across a range of studies intravenous infusion of GLP-1 has been demonstrated to acutely reduce food intake in human subjects<sup>(47)</sup>. GLP-1 receptors are expressed in many regions throughout the hypothalamus, with high levels in the ARC<sup>(48)</sup>. Abolishing ARC neuronal signalling eliminates the inhibitory effect of GLP-1 on food intake and appetite<sup>(49)</sup>. Similar to PYY, the action of circulating GLP-1 on appetite-regulatory circuits in the brain may in part be via the stimulation of peripheral vagal afferents<sup>(44)</sup>.

Due to the potent effects of PYY and GLP-1 on feeding behaviour, interventions that increase the circulating levels of these gut hormones are the target of many anti-obesity strategies. The discovery that FFAR2 and FFAR3 are co-localised with L-cells in the colon has led to the suggestion that activation of these receptors by SCFA ligands would facilitate PYY and GLP-1 release. Investigations using rodent primary colonic cultures have consistently shown that SCFA stimulate the release of PYY and GLP-1 from colonic L-cells<sup>(50–53)</sup>. Tolhurst *et al.*<sup>(53)</sup> observed that SCFA activation stimulated GLP-1 secretion from wild-type murine L-cells and these effects were significantly attenuated in FFAR2 knock-out (–/–) and FFAR3<sup>–/–</sup> cells. However, *in vivo*, only FFAR2<sup>–/–</sup>, but not FFAR3<sup>–/–</sup> mice, had significantly reduced circulating levels of GLP-1. It was found that FFAR2 enhances GLP-1 secretion by triggering an intracellular calcium response in the L-cell via the specific coupling of FFAR2 to G<sub>q</sub>-proteins. It was therefore suggested that the blunted response to SCFA observed in FFAR3<sup>–/–</sup> colonic cultures may be related to the reduced expression of FFAR2 observed in FFAR3<sup>–/–</sup> mice<sup>(35)</sup>. A recent investigation supports a primary role of FFAR2 in stimulating gut hormone release<sup>(54)</sup>. It was found that the SCFA propionate stimulates the secretion of both PYY and GLP-1 from wild-type primary murine colonic crypt cultures and this effect was significantly reduced in FFAR2<sup>–/–</sup> mice cultures. In addition, an *in vivo* model demonstrated that intra-colonic administration of propionate stimulates the simultaneous release of both GLP-1 and PYY in rodents and that this stimulatory effect was abolished in FFAR2<sup>–/–</sup> animals. These studies would therefore suggest that increasing the intake of fermentable dietary fibres and colonic production of SCFA would stimulate PYY and GLP-1 release. Indeed, a number of studies have reported that animals

fed high doses of fermentable fibres have increased endogenous secretions of PYY and GLP-1<sup>(55–59)</sup>, as well as an increased number of colonic L-cells<sup>(60)</sup>. In human subjects, it has been shown that adding 24 g of the fermentable fibre oligofructose to a test meal significantly increased GLP-1 levels in the postprandial period<sup>(61)</sup>. This finding is supported by an investigation that revealed that feeding 16 g oligofructose/d for 2 weeks significantly lowered subjective hunger ratings, which was associated with increased PYY and GLP-1 release during a test meal<sup>(62)</sup>. Furthermore, in a longer-term investigation, overweight volunteers were given 21 g oligofructose/d or a placebo for 12 weeks and the fermentable fibre intervention group experienced significant weight loss compared with the placebo group, which was associated with enhanced PYY release and reduced self-reported energy intake during the supplementation period<sup>(63)</sup>. Recent reports have suggested that the amount of fermentable fibre consumed in the diet is critical to observe an effect on gut hormone release, as it was found that the supplementation of 16 g oligofructose/d, but not 10 g/d, for 13 d stimulated postprandial PYY and GLP-1 release<sup>(64)</sup>. This would suggest that high daily intakes of fermentable fibres may be needed to produce the colonic concentrations of SCFA required to modulate PYY and GLP-1 release. This is supported by a recent dose-escalation study in healthy human participants completing a 5-week supplementation period where the daily intake of oligofructose increased from 15, 25, 35, 45, 55 g/d each week and it was found that intake of fermentable fibre exceeding 35 g/d was needed to elevate post-prandial PYY release<sup>(65)</sup>. In summary, available evidence suggests that SCFA are capable of stimulating the anorectic gut hormones PYY and GLP-1 from colonic L-cells, primarily via the activation of FFAR2. Consequently, with a sufficiently high dietary intake, fermentable fibres can elevate anorectic gut hormone profiles, through an increased colonic production of SCFA.

### SCFA and digestive tract motility

The GI tract contains mechanoreceptors and chemoreceptors that relay information to the central nervous system via vagal afferents, which contribute to the regulation of satiation and satiety<sup>(28)</sup>. It has been proposed that slowing the rate at which ingested food passes through the GI tract prolongs stimulation of these chemo- and mechanoreceptors, which in turn extends satiety following food intake<sup>(66,67)</sup>. For example, numerous studies have reported that delaying the gastric emptying of ingested food is associated with short-term effects on appetite and satiety measures<sup>(68,69)</sup>. The direct effect of luminal SCFA on colonic motility has been studied using *in vitro* and *in vivo* models. Squires *et al.*<sup>(70)</sup> reported that large concentrations of SCFA decreased colonic contractile activity when infused in an isolated rat colon. However, *in vivo* studies performed in human subjects have failed to indicate that SCFA directly modulate colonic motility. Recently, it has been reported that in twenty healthy human volunteers

intra-colonic infusion of a SCFA mixture had no direct effects on colonic motor activity, measured with perfused catheters and an electronic barostat<sup>(71)</sup>, supporting a previous observation involving two human subjects<sup>(72)</sup>. Nevertheless, SCFA may modulate motility of the upper digestive tract through the release of PYY and GLP-1. Cherbut *et al.*<sup>(51)</sup> observed that intraluminal infusion of SCFA into the rat colon significantly slowed gut transit rate. It was reported that the colonic infusion of SCFA released PYY in the peripheral circulation, suggesting that PYY could mediate the inhibitory effect of SCFA on gut motility. This hypothesis was supported by the finding that when colonic SCFA were administered following the immunoneutralisation of circulating PYY the effect of SCFA on gut transit rates was abolished. PYY is one of the hormones considered to mediate the 'ileal brake reflex', and studies have shown PYY to inhibit gastric emptying<sup>(73,74)</sup>. In addition, it has been found that elevating circulating levels of GLP-1 can also slow rates of gastric emptying<sup>(75,76)</sup>. Consequently, SCFA-stimulated release of PYY and GLP-1 from colonic L-cells may be capable of modifying appetite responses by delaying the gastric emptying of ingested foods and prolonging the stimulation of mechanoreceptors and chemoreceptors in the GI tract.

### Hepatic metabolism of propionate


As previously mentioned, the largest concentrations of SCFA are found in the proximal colon, where SCFA are rapidly absorbed by colonocytes. Measurements in isolated colonocytes have shown that the majority of the energy demands of colonocytes (about 70 %) are derived from oxidation of SCFA<sup>(77)</sup>. SCFA that are not metabolised by colonocytes are released from the gut via the hepatic and portal vein system and measurements in human subjects have found that the molar fractions of acetate, propionate and butyrate change from approximately 60 : 20 : 20 in the colonic lumen to 70 : 20 : 10 in the portal vein<sup>(19)</sup>, indicative of the preferential use of butyrate by mammalian colonocytes as an energy source<sup>(77,78)</sup>. SCFA that are not metabolised by the liver then enter the peripheral circulation, where the approximate molar fraction is changed to 90 : 5 : 5 for acetate, propionate and butyrate, respectively<sup>(19)</sup>. This demonstrates that the liver takes up a considerable amount of propionate from the circulation. Indeed, it has been estimated that about 90 % of propionate in the portal vein is extracted by the liver<sup>(79)</sup>. Propionate is a known precursor for hepatic gluconeogenesis<sup>(80)</sup>, where propionate is rapidly converted to propionyl-CoA and enters the TCA-cycle at the level of succinyl-CoA. This leads to an elevation in the levels of oxaloacetate, which is converted to glucose. Data obtained from animal models suggest that elevating hepatic energy status can modulate appetite and feeding behaviour through the stimulation of hepatic vagal afferents that signal to the nucleus of the solitary tract within the brainstem<sup>(81)</sup>. Evidence for a role of hepatic propionate metabolism as a satiety signal comes primarily from ruminant studies,

as it has been extensively reported that portal infusions of propionate depress energy intake in sheep and cows<sup>(82–84)</sup>. Furthermore, these hypophagic effects of elevating exogenous propionate in the portal vein are abolished with hepatic vagotomy or total liver denervation<sup>(85,86)</sup>. However, caution must be taken when considering ruminants as models to study appetite regulation in human subjects, as marked differences in energy utilisation exist between species. Ruminants must synthesise their entire glucose requirements via hepatic gluconeogenesis and exogenous propionate accounts for approximately 80 % of endogenous glucose production<sup>(87)</sup>. It is therefore unsurprising that, as a major energy substrate, propionate availability provides such a potent satiety signal in ruminant species. While much less is known about the effect of propionate on glucose production in man, the vast majority of exogenous propionate is metabolised by the liver and a recent investigation using an innovative labelling strategy, in combination with localised *in vivo* <sup>13</sup>C magnetic resonance spectroscopy, reported that elevating exogenous propionate supply to the human liver increased hepatic glucose production by 30 %<sup>(88)</sup>. As a key anabolic organ, which is estimated to contribute 20 % of resting energy expenditure in human subjects<sup>(89)</sup>, it is plausible that substantial changes in hepatic glucose production and storage could be sensed centrally to regulate feeding behaviour. An interesting area of future research would determine how increasing the concentrations of propionate produced in the human colon would alter hepatic intracellular signalling pathways related to energy status, and whether these changes to hepatic metabolic processes provide an anorectic neural signal to appetite-regulatory regions of the brain.

### SCFA and leptin secretion

SCFA that do not undergo hepatic metabolism enter the peripheral circulation, and concentrations in human peripheral blood of 170, 4 and 8 µmol/l have been reported for acetate, propionate and butyrate, respectively<sup>(90)</sup>. Furthermore, it has been demonstrated in human studies that elevating the fermentable fibre component of the diet raises SCFA levels in the peripheral blood<sup>(61,91–93)</sup>, particularly concentrations of acetate. Circulating SCFA have been shown to interact with different peripheral organ and tissue sites. In particular, it has been demonstrated that SCFA have a major regulatory role in adipocyte function and metabolism<sup>(34,36,94)</sup> and are reported to stimulate leptin secretion<sup>(35,95)</sup>. Circulating levels of leptin are proportional to fat mass and can cross the blood–brain barrier to induce an anorectic effect via the ARC, where both neuropeptide Y/agouti-related peptide and POMC/cocaine and amphetamine-regulated transcript neurons express leptin receptors<sup>(96)</sup>. Leptin inhibits neuropeptide Y/agouti-related peptide neurons and activates POMC/cocaine and amphetamine-regulated transcript neurons<sup>(97)</sup>, resulting in reduced energy intake. Leptin-deficient mice have been shown to exhibit hyperphagia and obesity, which can be reversed by leptin





**Fig. 1.** Increasing the colonic production of SCFA stimulates multiple hormonal and neural mechanisms that suppress appetite and energy intake. (1) Increasing the intake of dietary fibre increases the amount of fermentable substrate reaching the colon, which is fermented by resident microbiota elevating the production of SCFA. (2) SCFA stimulate the release of peptide tyrosine tyrosine (PYY) and glucagon-like-peptide-1 (GLP-1) via the activation of free fatty acid receptor 2 (FFAR2) on colonic L-cells. (3) Within the hypothalamic arcuate nucleus, peripheral PYY and GLP-1 increases the activity of the appetite-suppressing pro-opiomelanocortin (POMC)/ cocaine and amphetamine-regulated transcript (CART) neurons and inhibits appetite-stimulating neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons. (4) Increased circulatory PYY and GLP-1 would modulate central appetite regulation via the stimulation of peripheral vagal afferents that are integrated in the nucleus of the solitary tract (NTS) of the brainstem. (5) PYY and GLP-1 have also been shown to inhibit the motility of the upper gastrointestinal (GI) tract. This slows the gastric emptying of ingested foods and prolongs the stimulation of mechanoreceptors and chemoreceptors in the GI tract that signal centrally via vagal afferents. (6) Increased concentrations of propionate in the portal vein would be taken up by the liver and stimulate hepatic gluconeogenesis. An increased hepatic energy status can modulate feeding behaviour via the stimulation of hepatic vagal nerve afferents. (7) Increasing acetate and propionate in the peripheral circulation stimulates leptin release from adipocytes via activation of FFAR2. Leptin inhibits NPY/AgRP neurons and activates POMC/CART neurons. (8) Acetate can cross the blood-brain barrier and increase POMC and reduce AgRP expression.

administration<sup>(98)</sup>. In 2004, Xiong *et al.*<sup>95</sup> reported that FFAR3 was expressed in adipocytes and that SCFA could stimulate leptin expression in both a mouse adipocyte cell line and mouse adipose tissue in primary culture. Furthermore, it was found *in vivo* that elevating

circulating levels of propionate increased leptin levels in mice. Nevertheless, not all researchers have been able to detect FFAR3 in different adipose tissue sites<sup>(34,36,37)</sup>, thus the role of FFAR3 in adipose tissue function is currently a contentious topic. It has been

consistently reported that FFAR2 is abundantly expressed in white adipose tissue<sup>(34–36)</sup> and suggested that FFAR2 may be responsible for stimulating leptin release from adipocytes. It was found that leptin secretion from wild-type adipocytes was increased by acetate, yet butyrate had no significant effect<sup>(35)</sup>. Owing to the different activation potencies of FFAR2 and FFAR3 to acetate<sup>(29,30)</sup>, this would imply that FFAR2 is responsible for triggering leptin secretion. Furthermore, leptin secretion from FFAR2<sup>−/−</sup> mice adipocytes was lower compared with wild-types. While acetate was also found not to secrete leptin from FFAR3<sup>−/−</sup> mice adipocytes, this was suggested to be due to a reduced expression of FFAR2 in these cells rather than the abolishment of FFAR3 signalling. Finally, it has been demonstrated that the effects of FFAR2 on leptin release are due to G<sub>i/o</sub>-protein signalling, rather than a G<sub>q</sub>-protein-mediated mechanism, as leptin secretion by SCFA is prevented in the presence of pertussis-toxin, which inactivates G<sub>i/o</sub> signal transduction<sup>(35,99)</sup>. In summary, studies indicate that circulating SCFA, particularly acetate and propionate, can promote leptin secretion from adipocytes via activation of FFAR2, thus providing an anorectic signal to appetite-regulatory neurons in the hypothalamic ARC.

### Direct central effects of acetate on hypothalamic control of appetite

As previously stated, acetate is the most abundant end product of colonic fermentation of dietary fibre and circulates at considerably greater concentration compared with propionate and butyrate. There is evidence to suggest that acetate can travel across the blood–brain barrier into the central nervous system<sup>(100)</sup>, raising the possibility that SCFA may have a direct effect on central appetite regulation. Using an intravenous and colonic infusion of <sup>11</sup>C-acetate in mice and *in vivo* positron emission tomography-computed tomography scanning it was recently shown that up to 3% of exogenous acetate was taken up by the brain in both the fed and fasted states<sup>(101)</sup>. In particular, peripheral acetate was taken up by the hypothalamus in greater amounts than other brain tissues and it was found that within the hypothalamus acetate promotes an anorectic signal in the ARC, leading to increased POMC and reduced agouti-related peptide neuron expression. This investigation therefore provides a novel insight into the mechanism through which elevations in acetate production in the colon may mediate appetite suppression.

### Conclusions

SCFA produced through the fermentation of dietary fibre in the colon have been shown to exert multiple effects on various organ and tissue sites. The present review has proposed that SCFA could stimulate numerous hormonal and neural signals that would cumulatively exert a potent anorectic effect. Many of these possible mechanisms (summarised in Fig. 1) would be

strengthened with additional data from human studies, as the majority of the current available evidence to support a role of SCFA in appetite-regulation has been obtained from animal models, where direct translation into human subjects may be limited. Nevertheless, targeting the mechanisms through which SCFA suppress appetite through the development of novel dietary interventions that augment colonic SCFA production may be an effective strategy to improve appetite regulation and long-term weight management.

### Financial Support

The Section of Investigative Medicine, Imperial College is funded by grants from the MRC, BBSRC, NIHR, an Integrative Mammalian Biology Capacity Building Award, an FP7-HEALTH- 2009- 241592 EuroCHIP grant and is supported by the NIHR Imperial Biomedical Research Centre Funding Scheme. G. F. is supported by an NIHR senior investigator award. The work in SUERC is funded by the BBSRC and by a Scottish Government Strategic Partnership award in Food and Drink Science.

### Conflicts of Interest

None.

### Authorship

E. S. C. wrote the paper and had primary responsibility for final content. D. J. M. and G. F. were involved in refining the paper.

### References

1. Mozaffarian D, Hao T, Rimm EB *et al.* (2011) Changes in diet and lifestyle and long-term weight gain in women and men. *N Engl J Med* **364**, 2392–2404.
2. Peeters A, Magliano DJ, Backholer K *et al.* (2014) Changes in the rates of weight and waist circumference gain in Australian adults over time: a longitudinal cohort study. *BMJ Open* **4**, e003667.
3. Swinburn BA, Sacks G, Hall KD *et al.* (2011) The global obesity pandemic: shaped by global drivers and local environments. *Lancet* **378**, 804–814.
4. Zhai F, Wang H, Wang Z *et al.* (2008) Closing the energy gap to prevent weight gain in China. *Obes Rev* **9** Suppl 1, 107–112.
5. Ludwig DS, Pereira MA, Kroenke CH *et al.* (1999) Dietary fiber, weight gain, and cardiovascular disease risk factors in young adults. *JAMA* **282**, 1539–1546.
6. Maskarinec G, Takata Y, Pagano I *et al.* (2006) Trends and dietary determinants of overweight and obesity in a multi-ethnic population. *Obesity (Silver Spring)* **14**, 717–726.
7. Du H, van der AD, Boshuizen HC *et al.* (2010) Dietary fiber and subsequent changes in body weight and waist circumference in European men and women. *Am J Clin Nutr* **91**, 329–336.
8. Liu S, Willett WC, Manson JE *et al.* (2003) Relation between changes in intakes of dietary fiber and grain

- products and changes in weight and development of obesity among middle-aged women. *Am J Clin Nutr* **78**, 920–927.
9. Cummings JH, Mann JI, Nishida C *et al.* (2009) Dietary fibre: an agreed definition. *Lancet* **373**, 365–366.
  10. Slavin JL (2005) Dietary fiber and body weight. *Nutrition* **21**, 411–418.
  11. Wanders AJ, van den Borne JJ, de Graaf C *et al.* (2011) Effects of dietary fibre on subjective appetite, energy intake and body weight: a systematic review of randomized controlled trials. *Obes Rev* **12**, 724–739.
  12. Whitton C, Nicholson SK, Roberts C *et al.* (2011) National Diet and Nutrition Survey: UK food consumption and nutrient intakes from the first year of the rolling programme and comparisons with previous surveys. *Br J Nutr* **106**, 1899–1914.
  13. Eaton SB (2006) The ancestral human diet: what was it and should it be a paradigm for contemporary nutrition? *Proc Nutr Soc* **65**, 1–6.
  14. Frost GS, Walton GE, Swann JR *et al.* (2014) Impacts of plant-based foods in ancestral hominin diets on the metabolism and function of gut microbiota *in vitro*. *MBio* **5**, e00853–e00814.
  15. Topping DL & Clifton PM (2001) Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. *Physiol Rev* **81**, 1031–1064.
  16. Gill SR, Pop M, Deboy RT *et al.* (2006) Metagenomic analysis of the human distal gut microbiome. *Science* **312**, 1355–1359.
  17. Qin J, Li R, Raes J *et al.* (2010) A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* **464**, 59–65.
  18. Macfarlane S & Macfarlane GT (2003) Regulation of short-chain fatty acid production. *Proc Nutr Soc* **62**, 67–72.
  19. Cummings JH, Pomare EW, Branch WJ *et al.* (1987) Short chain fatty acids in human large intestine, portal, hepatic and venous blood. *Gut* **28**, 1221–1227.
  20. Royall D, Wolever TM & Jeejeebhoy KN (1990) Clinical significance of colonic fermentation. *Am J Gastroenterol* **85**, 1307–1312.
  21. Levrat MA, Remesy C & Demigne C (1991) High propionic acid fermentations and mineral accumulation in the cecum of rats adapted to different levels of inulin. *J Nutr* **121**, 1730–1737.
  22. Berggren AM, Björck IM, Nyman E *et al.* (1993) Short-chain fatty acid content and pH in caecum of rats given various sources of carbohydrates. *J Sci Food Agric* **63**, 397–406.
  23. Anastasovska J, Arora T, Sanchez Canon GJ *et al.* (2012) Fermentable carbohydrate alters hypothalamic neuronal activity and protects against the obesogenic environment. *Obesity (Silver Spring)* **20**, 1016–1023.
  24. Arora T, Loo RL, Anastasovska J *et al.* (2012) Differential effects of two fermentable carbohydrates on central appetite regulation and body composition. *PLoS ONE* **7**, e43263.
  25. Cummings JH, Beatty ER, Kingman SM *et al.* (1996) Digestion and physiological properties of resistant starch in the human large bowel. *Br J Nutr* **75**, 733–747.
  26. Jenkins DJ, Vuksan V, Kendall CW *et al.* (1998) Physiological effects of resistant starches on fecal bulk, short chain fatty acids, blood lipids and glycemic index. *J Am Coll Nutr* **17**, 609–616.
  27. Murphy KG & Bloom SR (2006) Gut hormones and the regulation of energy homeostasis. *Nature* **444**, 854–859.
  28. Hussain SS & Bloom SR (2013) The regulation of food intake by the gut-brain axis: implications for obesity. *Int J Obes (Lond)* **37**, 625–633.
  29. Brown AJ, Goldsworthy SM, Barnes AA *et al.* (2003) The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J Biol Chem* **278**, 11312–11319.
  30. Le Poul E, Loison C, Struyf S *et al.* (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. *J Biol Chem* **278**, 25481–25489.
  31. Nilsson NE, Kotarsky K, Owman C *et al.* (2003) Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. *Biochem Biophys Res Commun* **303**, 1047–1052.
  32. Karaki S, Tazoe H, Hayashi H *et al.* (2008) Expression of the short-chain fatty acid receptor, GPR43, in the human colon. *J Mol Histol* **39**, 135–142.
  33. Tazoe H, Otomo Y, Karaki S *et al.* (2009) Expression of short-chain fatty acid receptor GPR41 in the human colon. *Biomed Res* **30**, 149–156.
  34. Hong YH, Nishimura Y, Hishikawa D *et al.* (2005) Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. *Endocrinology* **146**, 5092–5099.
  35. Zaibi MS, Stocker CJ, O'Dowd J *et al.* (2010) Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. *FEBS Lett* **584**, 2381–2386.
  36. Kimura I, Ozawa K, Inoue D *et al.* (2013) The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. *Nat Commun* **4**, 1829.
  37. Kimura I, Inoue D, Maeda T *et al.* (2011) Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). *Proc Natl Acad Sci USA* **108**, 8030–8035.
  38. De Vadder F, Kovatcheva-Datchary P, Goncalves D *et al.* (2014) Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. *Cell* **156**, 84–96.
  39. Eissele R, Goke R, Willemer S *et al.* (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. *Eur J Clin Invest* **22**, 283–291.
  40. Adrian TE, Ferri GL, Bacarese-Hamilton AJ *et al.* (1985) Human distribution and release of a putative new gut hormone, peptide YY. *Gastroenterology* **89**, 1070–1077.
  41. Batterham RL, Cowley MA, Small CJ *et al.* (2002) Gut hormone PYY(3–36) physiologically inhibits food intake. *Nature* **418**, 650–654.
  42. Batterham RL, Cohen MA, Ellis SM *et al.* (2003) Inhibition of food intake in obese subjects by peptide YY3–36. *N Engl J Med* **349**, 941–948.
  43. Abbott CR, Small CJ, Kennedy AR *et al.* (2005) Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3–36) on food intake. *Brain Res* **1043**, 139–144.
  44. Abbott CR, Monteiro M, Small CJ *et al.* (2005) The inhibitory effects of peripheral administration of peptide YY (3–36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. *Brain Res* **1044**, 127–131.
  45. Koda S, Date Y, Murakami N *et al.* (2005) The role of the vagal nerve in peripheral PYY3–36-induced feeding reduction in rats. *Endocrinology* **146**, 2369–2375.
  46. Herrmann C, Goke R, Richter G *et al.* (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. *Digestion* **56**, 117–126.
  47. Verdich C, Flint A, Gutzwiller JP *et al.* (2001) A meta-analysis of the effect of glucagon-like peptide-1

- (7–36) amide on ad libitum energy intake in humans. *J Clin Endocrinol Metab* **86**, 4382–4389.
48. Goke R, Larsen PJ, Mikkelsen JD *et al.* (1995) Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. *Eur J Neurosci* **7**, 2294–2300.
  49. Tang-Christensen M, Vrang N & Larsen PJ (1998) Glucagon-like peptide 1(7–36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. *Diabetes* **47**, 530–537.
  50. Longo WE, Ballantyne GH, Savoca PE *et al.* (1991) Short-chain fatty acid release of peptide YY in the isolated rabbit distal colon. *Scand J Gastroenterol* **26**, 442–448.
  51. Cherbut C, Ferrier L, Roze C *et al.* (1998) Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat. *Am J Physiol* **275**, G1415–G1422.
  52. Anini Y, Fu-Cheng X, Cuber JC *et al.* (1999) Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. *Pflügers Arch* **438**, 299–306.
  53. Tolhurst G, Heffron H, Lam YS *et al.* (2011) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-Protein-Coupled receptor FFAR2. *Diabetes* **61**, 364–371.
  54. Psichas A, Sleeth ML, Murphy KG *et al.* (2014) The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. *Int J Obes (Lond)* (Epublication ahead of print version).
  55. Cani PD, Dewever C & Delzenne NM (2004) Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. *Br J Nutr* **92**, 521–526.
  56. Cani PD, Neyrinck AM, Maton N *et al.* (2005) Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1. *Obes Res* **13**, 1000–1007.
  57. Delmee E, Cani PD, Gual G *et al.* (2006) Relation between colonic proglucagon expression and metabolic response to oligofructose in high fat diet-fed mice. *Life Sci* **79**, 1007–1013.
  58. Zhou J, Hegsted M, McCutcheon KL *et al.* (2006) Peptide YY and proglucagon mRNA expression patterns and regulation in the gut. *Obesity (Silver Spring)* **14**, 683–689.
  59. Zhou J, Martin RJ, Tulley RT *et al.* (2008) Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. *Am J Physiol – Endocrinol Metab* **295**, E1160.
  60. Cani PD, Hoste S, Guiot Y *et al.* (2007) Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. *Br J Nutr* **98**, 32–37.
  61. Tarini J & Wolever TM (2010) The fermentable fibre inulin increases postprandial serum short-chain fatty acids and reduces free-fatty acids and ghrelin in healthy subjects. *Appl Physiol Nutr Metab* **35**, 9–16.
  62. Cani PD, Lecourt E, Dewulf EM *et al.* (2009) Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. *Am J Clin Nutr* **90**, 1236–1243.
  63. Parnell JA & Reimer RA (2009) Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. *Am J Clin Nutr* **89**, 1751–1759.
  64. Verhoef SP, Meyer D & Westerterp KR (2011) Effects of oligofructose on appetite profile, glucagon-like peptide 1 and peptide YY3–36 concentrations and energy intake. *Br J Nutr* **106**, 1757–1762.
  65. Pedersen C, Lefevre S, Peters V *et al.* (2013) Gut hormone release and appetite regulation in healthy non-obese participants following oligofructose intake. A dose-escalation study. *Appetite* **66**, 44–53.
  66. Hellstrom PM & Naslund E (2001) Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1. *Physiol Behav* **74**, 735–741.
  67. Janssen P, Vanden Berghe P, Verschueren S *et al.* (2011) Review article: the role of gastric motility in the control of food intake. *Aliment Pharmacol Ther* **33**, 880–894.
  68. Di Lorenzo C, Williams CM, Hajnal F *et al.* (1988) Pectin delays gastric emptying and increases satiety in obese subjects. *Gastroenterology* **95**, 1211–1215.
  69. Santangelo A, Peracchi M, Conte D *et al.* (1998) Physical state of meal affects gastric emptying, cholecystokinin release and satiety. *Br J Nutr* **80**, 521–527.
  70. Squires PE, Rumsey RD, Edwards CA *et al.* (1992) Effect of short-chain fatty acids on contractile activity and fluid flow in rat colon *in vitro*. *Am J Physiol* **262**, G813–G817.
  71. Jouet P, Moussata D, Duboc H *et al.* (2013) Effect of short-chain fatty acids and acidification on the phasic and tonic motor activity of the human colon. *Neurogastroenterol Motil* **25**, 943–949.
  72. Kamath PS, Phillips SF, O'Connor MK *et al.* (1990) Colonic capacitance and transit in man: modulation by luminal contents and drugs. *Gut* **31**, 443–449.
  73. Pappas TN, Debas HT, Chang AM *et al.* (1986) Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dogs. *Gastroenterology* **91**, 1386–1389.
  74. Lin HC, Zhao XT, Wang L *et al.* (1996) Fat-induced ileal brake in the dog depends on peptide YY. *Gastroenterology* **110**, 1491–1495.
  75. Naslund E, Gutniak M, Skogar S *et al.* (1998) Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. *Am J Clin Nutr* **68**, 525–530.
  76. Edholm T, Degerblad M, Gryback P *et al.* (2010) Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. *Neurogastroenterol Motil* **22**, 1191–1200, e1315.
  77. Clausen MR & Mortensen PB (1995) Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis. *Gut* **37**, 684–689.
  78. Ardawi MS & Newsholme EA (1985) Fuel utilization in colonocytes of the rat. *Biochem J* **231**, 713–719.
  79. Peters SG, Pomare EW & Fisher CA (1992) Portal and peripheral blood short chain fatty acid concentrations after caecal lactulose instillation at surgery. *Gut* **33**, 1249–1252.
  80. Al-Lahham SH, Peppelenbosch MP, Roelofs H *et al.* (2010) Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. *Biochim Biophys Acta* **1801**, 1175–1183.
  81. Allen MS, Bradford BJ & Oba M (2009) Board Invited Review: the hepatic oxidation theory of the control of feed intake and its application to ruminants. *J Anim Sci* **87**, 3317–3334.
  82. Elliot JM, Symonds HW & Pike B (1985) Effect on feed intake of infusing sodium propionate or sodium acetate into a mesenteric vein of cattle. *J Dairy Sci* **68**, 1165–1170.
  83. Farningham DA & Whyte CC (1993) The role of propionate and acetate in the control of food intake in sheep. *Br J Nutr* **70**, 37–46.
  84. Leuvenink HG, Bleumer EJ, Bongers LJ *et al.* (1997) Effect of short-term propionate infusion on feed intake and blood parameters in sheep. *Am J Physiol* **272**, E997–E1001.





85. Anil MH & Forbes JM (1980) Feeding in sheep during intraportal infusions of short-chain fatty acids and the effect of liver denervation. *J Physiol* **298**, 407–414.
86. Anil MH & Forbes JM (1988) The roles of hepatic nerves in the reduction of food intake as a consequence of intraportal sodium propionate administration in sheep. *Q J Exp Physiol* **73**, 539–546.
87. Allen MS, Bradford BJ & Harvatine KJ (2005) The cow as a model to study food intake regulation. *Annu Rev Nutr* **25**, 523–547.
88. Befroy DE, Perry RJ, Jain N *et al.* (2014) Direct assessment of hepatic mitochondrial oxidative and anaplerotic fluxes in humans using dynamic <sup>13</sup>C magnetic resonance spectroscopy. *Nat Med* **20**, 98–102.
89. Blundell JE, Caudwell P, Gibbons C *et al.* (2012) Role of resting metabolic rate and energy expenditure in hunger and appetite control: a new formulation. *Dis Model Mech* **5**, 608–613.
90. Bloemen JG, Venema K, van de Poll MC *et al.* (2009) Short chain fatty acids exchange across the gut and liver in humans measured at surgery. *Clin Nutr* **28**, 657–661.
91. Ferchaud-Roucher V, Pouteau E, Piloquet H *et al.* (2005) Colonic fermentation from lactulose inhibits lipolysis in overweight subjects. *Am J Physiol Endocrinol Metab* **289**, E716–E720.
92. Robertson MD, Bickerton AS, Dennis AL *et al.* (2005) Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. *Am J Clin Nutr* **82**, 559–567.
93. Nilsson AC, Ostman EM, Knudsen KE *et al.* (2010) A cereal-based evening meal rich in indigestible carbohydrates increases plasma butyrate the next morning. *J Nutr* **140**, 1932–1936.
94. Ge H, Li X, Weiszmann J *et al.* (2008) Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. *Endocrinology* **149**, 4519–4526.
95. Xiong Y, Miyamoto N, Shibata K *et al.* (2004) Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. *Proc Natl Acad Sci USA* **101**, 1045–1050.
96. Baskin DG, Breininger JF & Schwartz MW (1999) Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. *Diabetes* **48**, 828–833.
97. Sahu A (2003) Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. *Front Neuroendocrinol* **24**, 225–253.
98. Halaas JL, Gajiwala KS, Maffei M *et al.* (1995) Weight-reducing effects of the plasma protein encoded by the obese gene. *Science* **269**, 543–546.
99. Al-Lahham SH, Roelofsen H, Priebe M *et al.* (2010) Regulation of adipokine production in human adipose tissue by propionic acid. *Eur J Clin Invest* **40**, 401–407.
100. Song WS, Nielson BR, Banks KP *et al.* (2009) Normal organ standard uptake values in carbon-11 acetate PET imaging. *Nucl Med Commun* **30**, 462–465.
101. Frost G, Sleeth ML, Sahuri-Arisoylu M *et al.* (2014) The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. *Nat Commun* **5**, 3611.